ChemoCentryx Stock News

EXCLUSIVE: Dylan, 7, from Doncaster, was given a radical new treatment for Focal Segmental Glomerulosclerosis (FSGS) after his mum emailed a US doctor out of the blue asking for help in treating her s

ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to initiate clinical

BNP Paribas Arbitrage SA boosted its holdings in ChemoCentryx Inc (NASDAQ:CCXI) by 207.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The i

The

ChemoCentryx, Inc. (CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentryx also announced today that the underwriters of its follow-on

Federated Hermes Inc. raised its holdings in ChemoCentryx Inc (NASDAQ:CCXI) by 128.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commis

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

ChemoCentryx, Inc. (CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds t

ChemoCentryx, Inc. (CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 3

Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re

ChemoCentryx management is still delivering strong execution. Despite the recent announcement that the LUMINA-1 trial failed to meet its primary endpoint, there

MOUNTAIN VIEW, Calif., June 03, 2020 -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part.